Olaparib (Lynparza) in women who have advanced high-grade epithelial ovarian cancer with a BRCA mutation
In 2019, the Institute for Quality and Efficiency (IQWiG, Germany) looked into whether olaparib has any advantages or disadvantages compared with the watchful waiting approach in women who have advanced high-grade epithelial ovarian cancer with a BRCA mutation, are receiving platinum-based chemotherapy for the first time, and are benefiting from it.
The manufacturer provided one study involving a total of 391 women with usable data. Almost all of the women had serous ovarian cancer. The term "serous" refers to a certain characteristic of tumor tissue.
The study is still on-going, but an interim analysis was completed after about 5 years. Overall, 260 women in the study received olaparib and 131 women were given the standard treatment (watchful waiting). Early analyses suggest that olaparib has the following advantages and disadvantages: